{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T22:59:06Z","timestamp":1766530746922,"version":"build-2065373602"},"reference-count":33,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2013,6,12]],"date-time":"2013-06-12T00:00:00Z","timestamp":1370995200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diabetes Obesity Metabolism"],"published-print":{"date-parts":[[2013,11]]},"abstract":"Abstract<\/jats:title>\n \n Aim<\/jats:title>\n Assess influences of demographics and co\u2010morbidities of gout patients with or without diabetes on safety and efficacy of urate\u2010lowering agents.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n \n Post\u2010hoc analysis of 312 diabetic and 1957 non\u2010diabetic gout patients [baseline serum urate levels (\n sUA<\/jats:styled-content>\n ) \u22658.0\u2009mg\/dl] enrolled in a 6\u2010month randomized controlled trial comparing urate\u2010lowering efficacy (\n ULE<\/jats:styled-content>\n ) and safety of daily xanthine oxidase inhibitors (\n XOIs<\/jats:styled-content>\n ) febuxostat (40\u2009mg or 80\u2009mg) and allopurinol (200\u2009mg or 300\u2009mg). We compared baseline demographic, gout and co\u2010morbid characteristics,\n ULE<\/jats:styled-content>\n , and safety of\n XOI<\/jats:styled-content>\n treatment in diabetic and non\u2010diabetic gout patients.\n ULE<\/jats:styled-content>\n was measured by the proportion of diabetic and non\u2010diabetic patients in each treatment group achieving final visit\n sUA<\/jats:styled-content>\n \u2009<\u20096.0\u2009mg\/dl. Safety was monitored throughout the trial.\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Diabetic gout patients were older, more frequently female, and had longer gout duration. Co\u2010morbidities were more frequent among diabetic patients: cardiovascular disease; impaired renal function; hyperlipidemia; and obesity (body mass index >30\u2009kg\/m\n 2<\/jats:sup>\n ) (p\u2009<\u20090.001 for all comparisons). Febuxostat 80\u2009mg\n ULE<\/jats:styled-content>\n exceeded that of febuxostat 40\u2009mg or allopurinol (p\u2009<\u20090.050) at all levels of renal function, achieving\n sUA<\/jats:styled-content>\n goal range in the majority of diabetic and non\u2010diabetic patients. Diabetics and non\u2010diabetics reported self\u2010limiting diarrhoea and\n URIs<\/jats:styled-content>\n as the most common adverse events.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n \n Despite higher co\u2010morbidity rates in diabetic patients, febuxostat and allopurinol were safe in both groups at the doses tested. Febuxostat 80\u2009mg achieved\n sUA<\/jats:styled-content>\n <6.0\u2009mg\/dl more often than febuxostat 40\u2009mg or allopurinol at commonly prescribed doses.\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1111\/dom.12135","type":"journal-article","created":{"date-parts":[[2013,5,17]],"date-time":"2013-05-17T14:19:20Z","timestamp":1368800360000},"page":"1049-1055","source":"Crossref","is-referenced-by-count":28,"title":["Diabetes and gout: efficacy and safety of febuxostat and allopurinol"],"prefix":"10.1111","volume":"15","author":[{"given":"M. A.","family":"Becker","sequence":"first","affiliation":[{"name":"Pritzker School of Medicine The University of Chicago Chicago IL USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P. A.","family":"MacDonald","sequence":"additional","affiliation":[{"name":"Takeda Global Research & Development Center, Inc. Deerfield IL USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B. J.","family":"Hunt","sequence":"additional","affiliation":[{"name":"Takeda Global Research & Development Center, Inc. Deerfield IL USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R. L.","family":"Jackson","sequence":"additional","affiliation":[{"name":"Takeda Global Research & Development Center, Inc. Deerfield IL USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2013,6,12]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.055269"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.21772"},{"key":"e_1_2_7_4_1","first-page":"577","article-title":"Treatment of chronic gout. Can we determine when urate stores are depleted enough to prevent attacks of gout?","volume":"28","author":"Li\u2010Yu J","year":"2001","journal-title":"J Rheumatol"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.060368"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.10511"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2011.1169"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.080814"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.20405"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ken457"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rdc.2006.02.005"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.081604"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.22466"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.107.703389"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2369-12-36"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(84)90743-5"},{"key":"e_1_2_7_17_1","unstructured":"Allopurinol U.S. Prescribing Information. Apotex Corp Weston FL 2006."},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1525-139X.2007.00270.x"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.60.10.981"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.30119"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.076232"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.rhu.0000147049.12220.32"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ker373"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1210\/er.2008-0033"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ken305"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1186\/ar2978"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780200320"},{"key":"e_1_2_7_28_1","unstructured":"Kidney Disease Outcomes Quality Initiative (KDOQI). Clinical practice guidelines for chronic kidney disease: evaluation classification and stratification. Part 9. Approach to chronic kidney disease using these guidelines. National Kidney Foundation 2002; 1\u20139."},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1159\/000180580"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1097\/00003246-199310000-00016"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.4065\/81.7.925"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.308.6921.81"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(03)00659-3"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-201687"}],"container-title":["Diabetes, Obesity and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fdom.12135","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/dom.12135","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/dom.12135","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/pdf\/10.1111\/dom.12135","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T03:04:35Z","timestamp":1761879875000},"score":1,"resource":{"primary":{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/10.1111\/dom.12135"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,6,12]]},"references-count":33,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2013,11]]}},"alternative-id":["10.1111\/dom.12135"],"URL":"https:\/\/doi.org\/10.1111\/dom.12135","archive":["Portico"],"relation":{},"ISSN":["1462-8902","1463-1326"],"issn-type":[{"type":"print","value":"1462-8902"},{"type":"electronic","value":"1463-1326"}],"subject":[],"published":{"date-parts":[[2013,6,12]]}}}